Literature DB >> 3888384

Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.

G Parmiani, G Fossati, D Taramelli, A Anichini, A Balsari, C Gambacorti-Passerini, G Sciorelli, N Cascinelli.   

Abstract

Evidence for heterogeneity of several biological features of human malignant melanoma (Me) like morphology, cytogenetics, oncogenes activation, antigenic expression, metastatizing capacity and procoagulant activity are briefly reviewed in an attempt to distinguish findings related to primary vs. metastatic lesions. In our own studies monoclonal antibodies were used to study expression of MHC class I, class II products and of Me-associated antigens (MAA) on primary and metastatic Me cells. High expression of class I antigens was found in a high percentage of both primary and metastatic tumors, whereas DR and MAA showed a significant variation (from 3 to 90% of cells) in expression both in primary and in metastatic Me. When autologous cell-mediated immune responses were evaluated, it was found that Me cells from primary tumors but not those from lymph node metastases were able to stimulate autologous lymphocytes to proliferate and become cytotoxic for autologous Me. Clonal analysis of cytotoxic lymphocytes was then carried out in order to see whether the lack of lymphocytes reactivity to metastatic cells was due to the absence or to a low frequency of cytotoxic cells in the unstimulated PBL. CTL clones cytotoxic for autologous Me (Auto-Me) cells were indeed isolated. Three classes of CTL clones were identified: 1) one which is cytotoxic for Auto-Me; 2) a second one which lyse Auto-Me and allogeneic Me; and 3) a third one which is cytotoxic for Auto-Me and allogeneic normal and neoplastic cells. Metastatic Me cells, however, had the ability to suppress the stimulation of autologous PBL by alloantigens or IL-2. This effect was dose-dependent and was not due to absorption of IL-2 by Me cells. Since it has been reported that Me cells express class II MHC antigens, we investigated whether there was any correlation between autologous immune responses and DR expression on Me cells. Autologous lymphocytes stimulation was found to occur only with DR+ Me cells from primary lesions, whereas metastatic cells, either DR+ or DR-, did not stimulate autologous PBL. Moreover, the suppressive effect of metastatic Me cells was associated with their expression of DR antigens. The modulation of DR antigens on Me cells by Interferon-gamma correlated positively with their suppressive capacity. Thus, it appears that primary Me can behave differently from the metastatic one in their interactions with the immune system of autologous host. These findings suggest that DR antigens on Me cells may have an important role in the regulation of autologous immune responses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3888384     DOI: 10.1007/bf00047734

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  91 in total

1.  Differential sensitivites of human melanoma cells grown in vitro to arabinosylcytosine.

Authors:  S C Barranco; D H Ho; B Drewinko; M M Romsdahl; R M Humphrey
Journal:  Cancer Res       Date:  1972-12       Impact factor: 12.701

2.  Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?

Authors:  A P Albino; R Le Strange; A I Oliff; M E Furth; L J Old
Journal:  Nature       Date:  1984 Mar 1-7       Impact factor: 49.962

3.  Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes.

Authors:  G Fossati; D Taramelli; A Balsari; G Bogdanovich; S Andreola; G Parmiani
Journal:  Int J Cancer       Date:  1984-05-15       Impact factor: 7.396

4.  Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2.

Authors:  P Hersey; C Bindon; A Edwards; E Murray; G Phillips; W H McCarthy
Journal:  Int J Cancer       Date:  1981-12       Impact factor: 7.396

5.  Cytogenetics of human malignant melanoma and premalignant lesions.

Authors:  G Balaban; M Herlyn; D Guerry; R Bartolo; H Koprowski; W H Clark; P C Nowell
Journal:  Cancer Genet Cytogenet       Date:  1984-04

6.  Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions.

Authors:  P G Natali; R Cavaliere; A Bigotti; M R Nicotra; C Russo; A K Ng; P Giacomini; S Ferrone
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

7.  Inhibition of interleukin 2 production by factors released from tumor cells.

Authors:  P Hersey; C Bindon; M Czerniecki; A Spurling; J Wass; W H McCarthy
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

8.  Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.

Authors:  J E de Vries; H Spits
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

9.  Antigenic heterogeneity of clones and subclones from human melanoma cell lines demonstrated by a panel of monoclonal antibodies and flow microfluorometry analysis.

Authors:  C Cillo; J P Mach; M Schreyer; S Carrel
Journal:  Int J Cancer       Date:  1984-07-15       Impact factor: 7.396

10.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

Authors:  W G Dippold; K O Lloyd; L T Li; H Ikeda; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

View more
  5 in total

Review 1.  Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).

Authors:  C Gambacorti-Passerini; L Rivoltini; M Radrizzani; R Supino; M Mariani; G Parmiani
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

2.  Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes.

Authors:  D Taramelli; A Mazzocchi; C Clemente; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Interferon-mediated enhancement of metastasis. Are MHC antigens involved?

Authors:  P L Lollini; C De Giovanni; B Del Re; G Nicoletti; G Prodi; P Nanni
Journal:  Clin Exp Metastasis       Date:  1987 Oct-Dec       Impact factor: 5.150

Review 4.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  De materia medica versus codex alimentarius for the reinforcement of the gynecologic immune system: the case of endometriosis.

Authors:  Simon Vassiliadis
Journal:  Clin Med Insights Womens Health       Date:  2013-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.